ライフサイエンスコーパス: disease score

1 d-Turcotte-Pugh or Model for End-Stage Liver Disease scores).

2 rdioembolic Event, (female) Sex, or Vascular Disease] score).

3 s had similar age, model for end-stage liver disease score.

4 of transplant, and model for end-stage liver disease score.

5 g age, gender, and Model for End-Stage Liver Disease score.

6 o normal or gld recipients gave a diminished disease score.

7 lity together with Model for End-Stage Liver Disease score.

8 ensation, and high Model for End-Stage Liver Disease score.

9 egardless of their Model for End-Stage Liver Disease score.

10 , adjusted for age, sex, and CT small vessel disease score.

11 rb2 in vivo eliminates bacteria and improves disease score.

12 ents with relapsing-remitting MS with a high disease score.

13 y associated with the total MRI small vessel disease score.

14 s who had the same Model for End-Stage Liver Disease score.

15 ory cytokines, and model for end-stage-liver disease scores.

16 malized ratio, and Model for End-Stage Liver Disease scores.

17 ogenic immunization reproducibly ameliorated disease scores.

18 ration of clinical signs, and increased peak disease scores.

19 ents of mutant bone marrow, developed normal disease scores.

20 -Turcotte-Pugh and Model for End-stage Liver Disease scores.

21 tients with higher model for end-stage liver disease scores.

22 alth independent of improvements in physical disease scores.

23 three expression modules correlated with GLS disease scores.

24 oth Child-Pugh and Model for End-Stage Liver Disease scores.

25 l disease stage and model of end-stage liver disease scoring.

26 tium to Establish a Registry for Alzheimer's Disease score, 1.2 [0.5] vs 1.4 [0.8], respectively; P =

27 ; 35% female; mean Model for End-stage Liver Disease score, 10.8; range, 6-40) underwent MRI.

28 8.3 (+/-1.3), and Model for End-Stage Liver Disease score 11.7 (+/-3.9).

29 7 +/- 3; and mean model for end-stage liver disease score, 13 +/- 6) completed the program.

30 tage Liver Disease/Pediatric End-Stage Liver Disease score (19 vs 11, respectively; P = .48), and don

31 ars; 61% men; mean model for end-stage liver disease score, 19.5).

32 e analyzed (median Model for End-Stage Liver Disease score 20).

33 a higher mean (SD) model for end-stage liver disease score (24 [11] vs. 22 [10], P</=0.05).

34 ing DC had greater Model for End-stage Liver Disease scores (33 vs 27; P < .001); more frequent pretr

35 A pediatric end -stage liver disease score 40, postoperative hospital stays, rejectio

36 e-Pugh score 7 and Model for End-Stage Liver Disease score 6-29) were enrolled, 26 had hepatocellular

37 Pugh score >=7 and Model for End-Stage Liver Disease score 6-29) were enrolled, 26 had hepatocellular

38 cirrhosis (median Model for End-Stage Liver Disease score, 9; interquartile range, 7-13), and their

39 in group A and had a higher mean concomitant disease score, a higher proportion of men and a greater

40 Phenotypic data, including raw disease scores, a 'difference phenotype' (inoculated vs.

41 neurologic deficits as indicated by clinical disease score, activity monitoring, and footprint analys

42 lementation of the model for end-stage liver disease score and a concomitant increase on the rate of

43 asis of the current model of end-stage liver disease score and cDCD-NRP risk score.

44 d increased median model for end-stage liver disease score and creatinine at the time of waitlisting.

45 tion was evidenced primarily by increases in disease score and degree of inflammation in the CNS.

46 identical sex and 2% based on identical NAS disease score and fibrosis grade.

47 Recipient Model for End-stage Liver Disease score and graft size were not significant predic

48 T to LT, and lower model for end-stage liver disease score and maximum tumor diameter (C-statistic 0.

49 Disease score and paw thickness were measured daily.

50 ment RRMS subjects inversely correlated with disease score and progression.

51 tium to Establish a Registry for Alzheimer's Disease scores and Braak and Braak stage), and hippocamp

52 er two strains, based on significantly lower disease scores and observably smaller and fewer lesions

53 ciated with higher model for end-stage liver disease scores and receiving a LT from a living donor.

54 luding with Porphyromonas that correlated to disease scores and salivary levels of interleukin (IL)-1

55 istologic sections were used to evaluate EAU disease scores and to assess outer blood retina barrier

56 hinge on regional model for end-stage liver disease scores and waiting time for transplant.

57 c vascular disease and cerebral small vessel disease scores and, in the multiple sclerosis group, the

58 tis C virus (HCV), model for end-stage liver disease score, and acute rejection; and donor age and ra

59 lysis requirement, model for end-stage liver disease score, and alcoholic liver disease.

60 by a higher median Model for End-Stage Liver Disease score, and associated with increased 90-day mort

61 s, calibrating the pediatric end-stage liver disease score, and deciding whether to accept an offered

62 x, race/ethnicity, Model for End-Stage Liver Disease score, and liver transplantation (adjusted hazar

63 h of stay, greater Model for End-stage Liver Disease score, and longer warm and cold ischemia times (

64 omorbidity burden, Model for End-Stage Liver Disease score, and serum level of albumin that predicts

65 younger age, lower Model for End-stage Liver Disease score, and shorter time from listing to first do

66 dysfunction, high model for end-stage liver disease score, and single LTx.

67 old ischemia time, model for end-stage liver disease score, and steatosis.

68 e weighting of the model for end-stage liver disease score, and the increased prevalence of nonalcoho

69 admissions during the previous year, chronic disease score, and use of non-statin lipid-lowering drug

70 age, coinfection, Model for End-Stage Liver Disease scores, and other potential confounders in a pro

71 ase-expressing virus), significantly reduced disease scores, and resulted in greater survival (P < 0.

72 icant correlations between interstitial lung disease score at CT and age or percentage predicted FVC,

73 igher median (IQR) Model for End-stage Liver Disease score at listing (35.0 [29.0-39.0] vs 20.0 [13.0

74 3 cm (P=0.02) and model for end-stage liver disease score at listing more than 11 (P=0.04) were inde

75 Disease/Pediatric Model for End-Stage Liver Disease score at LT significantly decreased across all a

76 ansplanted, median model for end-stage liver disease score at LT was 7 ((interquartile range [IQR]: 6

77 0.041), and lower Model for End-Stage Liver Disease score at the time of LT (23 vs. 29, P = 0.007).

78 , body weight, and pediatric end-stage liver disease score at the time of transplant were 13 months,

79 cantly higher mean Model for End-Stage Liver Disease score at time of waitlist registration than othe

80 owever, the median model for end-stage liver disease score at transplant (MMAT) is calculated based o

81 ased on the median model for end-stage liver disease score at transplant minus 3 (MMAT-3) of recipien

82 Mean Model for End-Stage Liver Disease score at transplant was significantly different

83 ee groups based on Model for End-Stage Liver Disease score at transplant: lower-score (regions 3, 10,

84 nger age and lower Model for End-Stage Liver Disease scores at listing were associated with an increa

85 rk so that patient model for end-stage liver disease scores at transplant is more uniform across regi

86 (AUROC = 0.70) and Model for End-Stage Liver Disease scores (AUROC = 0.83).

87 classical exposure measurement error using a disease score-based approach to standardization to the e

88 We constructed a 10-point Binswanger disease score (BDS) with subjective and objective diseas

89 impairment and high model of end-stage liver disease scores before liver transplantation (LT) are inc

90 , the dichotomized model for end-stage liver disease score below and above the median, and the presen

91 ied recipient age, Model for End-Stage Liver Disease score, body mass index, diabetes, and dialysis b

92 ory and allocation Model for End-stage Liver Disease scores (both P < 0.001).

93 tium to Establish a Registry for Alzheimer's Disease score, Braak stage score and clinical dementia r

94 ammonia levels or model for end-stage-liver disease scores, but patients in the rifaximin group had

95 on Comorbidity Index (c = 0.653) and Chronic Disease Score (c = 0.608) were similar discriminators of

96 nd was better than Model for End-Stage Liver Disease score (C-statistic 0.76).

97 nd mathematical models of prognosis in liver disease scores calculated at day 0, day 3, and day 7.

98 s, we developed a second and age independent disease score, called DRSA.

99 The disease score can be used to establish a criterion and t

100 adjusting for age, model for end-stage liver disease score, cardiovascular risk index, history of cor

101 Stratified by model for end-stage liver disease score categories 6 to 14, 15 to 24, 25 to 34, an

102 45, c = 0.745) than medication-based Chronic Disease Score (CDS)-1 and CDS-2 (c = 0.738, c = 0.718).

103 copic Score (MES) to generate the Cumulative Disease Score (CDS).

104 EDI, size of HCC, model for end-stage liver disease score, Child-Pugh score were not statistically s

105 g for age, gender, Model for End-Stage Liver Disease score, Child-Pugh score, serum sodium, previous

106 disease including Model for End-Stage Liver Disease score compared to middle aged and older adults (

107 t groups showed a significant improvement in disease score compared to the control group.

108 se activity, with the IRAMS showing enhanced disease scoring compared to standard EAE scoring methods

109 refore, the effect of the routine use of the disease score could result in fewer patients with severe

110 osts, and baseline Model for End-Stage Liver Disease score (DCC analysis only).

111 Pediatric End-Stage Liver Disease scores decreased from 16 +/- 4.6 to -1.2 +/- 4.6

112 ntation at a lower model for end-stage liver disease score, decreased death on waitlist, and excellen

113 efficacy was evidenced by a reduced clinical disease score, decreased expression of various inflammat

114 e immunization in such mice produced similar disease scores, demonstrating that Fas/FasL interactions

115 , body mass index, model for end-stage liver disease score, diabetes, functional status at transplant

116 months; Child and Model for End-Stage Liver Disease scores did not change.

117 The effects of disease distribution (disease score [DS]) and complexity of surgery (complexit

118 onist treatment also resulted in exacerbated disease scores, elevated proinflammatory mediators, and

119 tium to establish a registry for Alzheimer's disease score for neuritic plaques between, but Lewy bod

120 tium to Establish a Registry for Alzheimer's Disease score for neuritic plaques, p = 6.8 x 10-6) and

121 2 points on their Model for End Stage Liver Disease score for signing a donor card, 0.1 points for a

122 ys (OR 10.23), and Model for End-Stage Liver Disease score greater than 21 (OR 2.5) were significant.

123 ter than 55 years, Model for End-Stage Liver Disease score greater than 27, history of prior OLT grea

124 on of CRE post-LT, Model for End-Stage Liver Disease score greater than 32, combined transplantation,

125 coholic hepatitis (Model for End-Stage Liver Disease score > or = 15) were enrolled and randomized to

126 s mice showing the severe disease phenotype (disease score > or = 3)and 68 backcross mice of the resi

127 years; 48.0% had a Model for End-Stage Liver Disease score >/=20.

128 Model for End-Stage Liver Disease score >/=25 was associated with a lower 12-month

129 gen >27] + 0.4574 [Model for End-Stage Liver Disease score >21] + 1.1625 [intensive care unit days >3

130 ld-Pugh class C or model for end-stage liver disease score >=19) were eligible.

131 et drug use (nonaspirin), albumin <3.0 g/dL, disease score >=2 (according to the Charlson Comorbidity

132 0.03-0.99), and a model for end-stage liver disease score >=25 (HR, 0.26; 95% CI, 0.08-0.92).

133 A pediatric end -stage liver disease score >=40, postoperative hospital stays, reject

134 creatinine in the model for end-stage liver disease score has significantly increased the incidence

135 in recipients with model of end-stage liver disease score higher than 27 (13.2% vs. 23.0%, P < 0.001

136 nd inflammation were quantified by gross gut disease scoring, histologic scoring, type I collagen, an

137 01] and laboratory Model for End-stage Liver Disease score (HR = 1.01; 95% CI, 1.00-1.01) as independ

138 -2.12), and a high Model for End-stage Liver Disease score (HR, 1.02; 1.00-1.04).

139 is also identified Model for End-Stage Liver Disease score, hypovolemic shock, and bacterial infectio

140 oid insufficiency, Model for End-Stage Liver Disease score, hypovolemic shock, hepatocellular carcino

141 -Turcotte-Pugh and model for end-stage liver disease scores improved significantly from baseline to 6

142 trials by addressing issues of standardizing disease scoring, improving the sensitivity and precision

143 integrated with the model of end-stage liver disease score in a donor-recipient (D-R) matching system

144 concept validity of a total MRI small vessel disease score in CAA.

145 r of relapses and diminished mean cumulative disease score in chronic relapsing animals.

146 JNJ-61803534 significantly inhibited disease score in the imiquimod-induced mouse skin inflam

147 ticeable for lower model for end-stage liver disease scores in LD recipients (P<0.001) and younger do

148 dy to CLEC12A that significantly ameliorated disease scores in MOG35-55-induced progressive, as well

149 The data indicate that high disease scores in response to IRBP and p161-180 were fou

150 0; however, median Model for End-Stage Liver Disease scores in this BMI group were higher than those

151 e Charlson Comorbidity Index and the Chronic Disease Score, in assessing the comorbidity-attributable

152 -Turcotte-Pugh and model for end-stage liver disease scores, in patients with cirrhosis.

153 (age of recipient, model for end-stage liver disease score, indication for LT, platelet count, and re

154 pment of overt HE, Model for End-Stage Liver Disease score, low sodium, and age.

155 The group with severe disease scored lower than the norm across all domains (E

156 otics, exhibiting improved survival, reduced disease score, lower levels of serum cytokines, and impr

157 raft survival than Model for End-Stage Liver Disease score <15 (P=0.02).

158 n and a calculated model for end-stage liver disease score <15 at HCC diagnosis.

159 to those with lower Model of End-Stage Liver Disease scores (</=15).

160 recipients with low model of end-stage liver disease scores (<27), without hepatitis C, not hospitali

161 The Model for End-Stage Liver Disease score may have eliminated racial disparities on

162 8%), and had lower model for end-stage liver disease scores (median 9 versus 10) (all P < 0.05).

163 ege Criteria (KCC), Model of End Stage Liver Disease score (MELD), and serum sodium based modificatio

164 Adults with NIU with systemic disease scored notably lower on both Mental Component Su

165 l [CI], 2.1-13.8), Model for End-Stage Liver Disease score (odds ratio, 1.11; 95% CI, 1.04-1.17), and

166 D angiographic score of 0), mild-to-moderate disease (score of 1 to 3), and severe disease (score of

167 derate disease (score of 1 to 3), and severe disease (score of 4 to 6) had median F11R plasma levels

168 ntation included a Model for End-stage Liver Disease score of <=25, specific anatomical characteristi

169 noma with a native Model for End-Stage Liver Disease score of 10.

170 8 years and median model for end-stage liver disease score of 11 (range: 6-32).

171 gh B/C with a mean model for end-stage liver disease score of 12.0.

172 30.0 kg/m(2)), and model for end-stage liver disease score of 15 (IQR: 11-19) were included.

173 ited with a median Model for End-Stage Liver Disease score of 19.

174 ated with having a model for end-stage liver disease score of 20 or greater (hazards ratio, 2.90; 95%

175 11.7 years with a mean Model End-Stage Liver Disease score of 22.6 +/- 9.8.

176 p, or as a single dose upon acquisition of a disease score of 3 (late therapy group.

177 100%), and median model for end-stage liver disease score of 39.

178 87%) with a median Model for End-Stage Liver Disease score of 8 (range 6-15).

179 ugh a good correlation was found between the disease score of individual mice and some readout parame

180 dates with a final Model for End-stage Liver Disease score of less than 15.

181 acute rise in the Model for End-Stage Liver Disease score of more than 5 within 4 weeks before trans

182 iver when they had Model for End-stage Liver Disease scores of 15 or greater (P = .005).

183 ovided by studies of C3 knockout mice, where disease scores of gC-null virus were significantly highe

184 obal rating of the change in the severity of disease, scored on a scale of -3.0 to 3.0 at one year, w

185 sis and with worse Model for End-Stage Liver Disease score or diabetes, those taking prophylactic ant

186 post-ECP were compared with changes in skin disease scores or global organ involvement, or the abili

187 asures, paw swelling (P < 0.01) and clinical disease score (P < 0.0001).

188 (P < 0.001), worse Model for End-Stage Liver Disease score (P < 0.001), more portosystemic collateral

189 ion (P < 0.01), and nonalcoholic fatty liver disease score (P < 0.03).

190 gistic regression model showed that only the disease score (P <0.0005) was significantly associated w

191 0002) and lower model for end stage of liver disease scores (p = 0.03).

192 arance (cCrCl) and Pediatric End-Stage Liver Disease score (PELD).

193 : Child-Pugh class, model of end-stage liver disease score, pre- and post-DIPS PSGs, pre-DIPS liver f

194 tium to Establish a Registry for Alzheimer's Disease scores, presence of alpha-synuclein and TAR DNA-

195 y lower laboratory model for end-stage liver disease scores, pretransplant alpha fetoprotein, and cum

196 Model for End-Stage Liver Disease score pretransplantation and the number of acute

197 The disease score provides an objective means to quickly det

198 An increase in the disease score provides evidence that a new treatment pla

199 ificantly with the Model for End-Stage Liver Disease score (r = -0.39, P < 0.05), fasting venous ammo

200 lure as assessed by model for endstage liver disease score (r = 0.41, P = 0.006) and Maddrey's discri

201 ally and summed to give a total small vessel disease score (range 1-4) in each cohort separately, the

202 ces (a measure of day of onset and sustained disease scores) ranging from 367 to 663 with central ner

203 to a prespecified ordinal total small vessel disease score, ranging from 0 to 6 points.

204 Seventy-six subjects with a Rasmussen Disease Score (RDS) of 6 or higher were randomized doubl

205 PN-dependent, the Pediatric End-Stage Liver Disease score remained normal throughout the follow-up p

206 considered if the Model for End-Stage Liver Disease score remains greater than 17 after 3 months of

207 outcomes, as measured by ordinal severity of disease scores, requiring longer time to improvement (ad

208 ors associated with disease persistence were disease score (SCORAD), involvement of the limbs, flexur

209 ice on average had lower cumulative clinical disease scores, shorter duration of clinical signs, and

210 or equal to 32 or Model for End-Stage Liver Disease score (starts at 6 and capped at 40; worst = 40)

211 in recipient age, model for end-stage liver disease score, steatosis, and ischemia times for the pea

212 cted C57BL/6 mice with this drug reduced the disease score substantially with a 93% decrease in the v

213 counted for by the model for end-stage liver disease scoring system and may benefit from the increase

214 A disease scoring system has been developed using 10 tests

215 he combination of risk score and periodontal disease score than by either score alone.

216 milar earlier onset and more severe clinical disease score than WT mice engrafted with WT bone marrow

217 sed to obtain a global cerebral small vessel disease score that captured the presence and/or severity

218 with BM only, BM+T mice had higher systemic disease scores that correlated with tear fluid loss and

219 opensity score and Model for End-Stage Liver Disease score, the NSBB adjusted odds ratio for 6-week m

220 As judged by disease scores, three of the strains were susceptible, o

221 P = 0.03) and United Kingdom endstage liver disease score (UKELD) score (59 versus 57, P = 0.01) sig

222 the United Kingdom Model of End Stage Liver Disease score (UKELD) were calculated and area under the

223 ve prostate cancer phenotype with linkage-of-disease scores up to 2.16 and nonparametric linkage scor

224 ication method allows for timepoint-specific disease scores using morphological and physiological mea

225 erimental autoimmune encephalomyelitis (EAE) disease scores via the ligand-activated transcription fa

226 dly reduced virulence in vivo as measured by disease scores, virus titers, and mortality.

227 The P value for the disease score was <0.0005, and the P value for the risk

228 edian preoperative model for end-stage liver disease score was 12.

229 ears, and the mean model for end-stage liver disease score was 12.2 +/- 4.6.

230 Median Model for End-stage Liver Disease score was 14 (range, 7-22).

231 The mean Model for End-Stage Liver Disease score was 14.5 +/- 4.

232 Model for End-Stage Liver Disease score was 15 (IQR, 11-21); cold ischemia time, 8

233 Median (range) model for end-stage liver disease score was 16 (6-39).

234 female, and median Model for End-Stage Liver Disease score was 20.

235 The average Model for End-Stage Liver Disease score was 33.

236 Higher model for end-stage liver disease score was associated with increased graft failur

237 The mean end change in disease score was compared between groups.

238 The Model for End-Stage Liver Disease score was lower in the DCD SLK group (23 vs 29,

239 The United Kingdom End-Stage Liver Disease score was not associated with overall posttransp

240 The baseline Model for End-Stage Liver Disease score was not predictive of long-term outcome, w

241 5%-21.3%); the mean nonalcoholic fatty liver disease score was reduced from 5 (IQR, 4-5) to 1 (IQR, 1

242 The median model for end-stage liver disease score was similar between the genders.

243 Agreement between CT and MR imaging disease scores was assessed by using the kappa test.

244 proposed MELD and Pediatric End-stage Liver Disease scores was assessed using Harrell's concordance

245 and lower baseline Model for End-Stage Liver Disease score were associated with better survival.

246 oints added to the Model for End Stage Liver Disease score were associated with lower waitlist mortal

247 ille model and the Model for End-Stage Liver Disease score were independently associated with 6-month

248 Mean model for end-stage liver disease scores were 21.64 in the HCV group and 21.30 in

249 Disease scores were analyzed in reconstituted mice and c

250 ate Child-Pugh and Model for End-Stage Liver Disease scores were recorded.

251 seline (P = .001); Model for End Stage Liver Disease scores were reduced by 40.4% and 33%, respective

252 During the development of colitis, clinical disease scores were reduced by 50% (P < 0.001), and hist

253 Average clinical disease scores were significantly lower in peptide treat

254 were depleted of Vgamma4(+) cells, clinical disease scores were significantly reduced and the incide

255 ly correlated with Model for End-Stage Liver Disease score, whereas CFBa and CFD were positively asso

256 tium to Establish a Registry for Alzheimer's Disease score, which describes the density of neuritic p

257 tween social disadvantage and CMR or chronic disease scores while adjusting for childhood covariates

258 An enhanced automated method of disease scoring would eliminate subjectivity and reduce

259 isk Index with the model for end-stage liver disease score yields an AUC-ROC of 0.764 (95% CI, 0.756-